Evidence and cautions
A low fee leaves care questions open. Ask what the medicine is, who prepares it and why it is being proposed for you.
The Food and Drug Administration has the job of regulating US drugs. We use FDA as a short name for it.
According to FDA material checked in September 2026, some patients need compounding because an approved medicine cannot meet their needs.
There is no FDA approval for the finished compounded medicine. A compounded drug reaches the market without prior FDA review of its quality, effectiveness or safety.
Read about the role of compoundingIn the rule checked in September 2026, a listing or registration did not grant FDA approval. Being registered or listed did not by itself mean the product could legally be advertised or sold.
Ask for the exact product name instead of treating a registration badge as the whole answer.
Read what registration does establishFDA’s September 2026 concerns include weight-drug products sent to consumers under research labels, with directions for people to use them.
The agency warns that their quality is unknown and they could hurt people.
A research label does not answer a patient’s care questions.
Read the FDA consumer concernsThe federal rules checked in September 2026 restrict how often pharmacies and doctors may make copies of medicines already sold. Making large amounts of those copies is also restricted. Larger compounding facilities have separate federal restrictions on copying approved drugs.
Here, “prescriber” means the person who writes the prescription, such as a doctor.
For one named patient, a pharmacy or doctor may use an exception when the prescriber judges that changing the medicine makes a significant difference for that patient.
FDA gives the example of a patient who cannot use a ready-made medicine because of an allergy to its dye.
A price cut on its own does not meet that test.
Neither tirzepatide nor semaglutide injections appeared on the shortage list checked in September 2026.
An official shortage can permit compounding that would otherwise be restricted. That shortage exception ends when the shortage ends.
After FDA took these injections off its shortage list, pharmacies and larger compounding facilities had extra time to stop making copies under that exception. By September 2026, that extra time had ended for both injections.
Read the FDA update on copiesHave the prescriber describe the change and explain the benefit it is meant to make for you. Ask the pharmacy to explain which rule allows it to supply that preparation.
The September 2026 FDA record includes reports of errors with compounded semaglutide injections, some involving hospital care.
FDA’s reports describe mistakes by people measuring the amount for their own injections and by health professionals working out the amount.
Before an injection, ask whether your medicine comes ready to use or whether you would need to measure it. Have the pharmacist explain the label and how to use the supplied device. If the amount or instructions are unclear, get them clarified before going ahead.
Read the FDA alert about these errorsPatients can submit a suspected medicine problem through MedWatch, FDA’s free reporting service.
Reporting a concern and getting care for it are separate tasks. Take personal medical questions to a care professional.
Open MedWatch to report a problemKeep reading
Return to the questions to ask a service